Chronic consumption of an inositol-enriched carob extract improves postprandial glycaemia and insulin sensitivity in healthy subjects: A randomized controlled trial

Clin Nutr. 2016 Jun;35(3):600-7. doi: 10.1016/j.clnu.2015.05.005. Epub 2015 May 23.

Abstract

Background & aims: Inositols are thought to be mediators of the insulin signalling pathway. We assessed the effects of inositols on glycaemic control in fasting and postprandial states and evaluated lipoprotein profile and LDL particle size in healthy population.

Methods: A 12-week double-blind clinical trial was performed with forty healthy subjects administered either an inositol-enriched beverage (IEB) -containing 2.23 g of inositols in 250 ml- or a sucrose-sweetened beverage (SB) twice a day. Anthropometric measurements, fasting glucose levels, insulin and HOMA-IR index, lipoprotein profile and postprandial glucose concentrations (measured using the continuous glucose monitoring system (CGMS)) were recorded throughout the intervention period.

Results: Following the 12-week trial subjects receiving the IEB exhibited a significant decrease in insulin, HOMA-IR and Apo B and an increase in LDL particle size, whereas the SB group showed increases in BMI and fasting glucose concentration. Analysis of postprandial glucose levels at breakfast, lunch and dinner revealed a mean reduction of glucose of ≈14% and a significant reduction in the area under the curve at 24 h after consumption of the IEB.

Conclusions: Our results show that chronic IEB supplementation induces a significant improvement in carbohydrated metabolism parameters in healthy subjects.

Keywords: Carob pod extract; Continuous glucose monitoring system; Healthy subjects; Inositols; LDL particle size; Pinitol.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Blood Glucose / analysis
  • Dietary Supplements* / adverse effects
  • Double-Blind Method
  • Fabaceae / chemistry*
  • Female
  • Fruit / chemistry
  • Humans
  • Hyperglycemia / blood
  • Hyperglycemia / epidemiology
  • Hyperglycemia / metabolism
  • Hyperglycemia / prevention & control*
  • Hyperlipidemias / blood
  • Hyperlipidemias / epidemiology
  • Hyperlipidemias / metabolism
  • Hyperlipidemias / prevention & control
  • Hypoglycemic Agents / adverse effects
  • Hypoglycemic Agents / therapeutic use*
  • Hypolipidemic Agents / adverse effects
  • Hypolipidemic Agents / therapeutic use
  • Inositol / adverse effects
  • Inositol / analogs & derivatives*
  • Inositol / therapeutic use
  • Insulin Resistance*
  • Lipoproteins, IDL / blood
  • Lipoproteins, IDL / chemistry
  • Male
  • Monitoring, Ambulatory
  • Particle Size
  • Plant Extracts / adverse effects
  • Plant Extracts / therapeutic use*
  • Postprandial Period
  • Seeds / chemistry
  • Spain / epidemiology

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Hypolipidemic Agents
  • Lipoproteins, IDL
  • Plant Extracts
  • pinitol
  • Inositol